Newsletter

Click here to join
our newsletter.

Investors & Media

Whats new.

Press releases

Press releases.

Operational Update

December 12th 2017
press releases

Prima BioMed Becomes Immutep

November 28th 2017
press releases

Prima Secures European Patent Grant for Lead Product IMP321 in Cancer

November 22nd 2017
press releases

Investor updates

Investor updates.

Investor Update - December 2017

December 21st 2017
investor updates

Investor Update Edition 21

October 1st 2017
investor updates

Investor Update Edition 20

August 1st 2017
investor updates

Analyst reports

Analyst reports.

EDISON - Encouraging LAG-3 combo data at SITC

December 12th 2017
analyst reports

Maxim - IMP321 + Keytruda: Positive Data in Melanoma to be Presented at SITC

November 28th 2017
analyst reports

Maxim - IMP321 (LAG-3Ig) Heating up the T cell Response for Keytruda in Melanoma - New Data To Be Presented at-SITC

November 15th 2017
analyst reports